Next Article in Journal / Special Issue
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
Previous Article in Journal / Special Issue
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
Article Menu

Export Article

Open AccessReview
Vaccines 2018, 6(3), 55;

Therapeutic Vaccines for Genitourinary Malignancies

Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Author to whom correspondence should be addressed.
Received: 17 July 2018 / Accepted: 6 August 2018 / Published: 12 August 2018
(This article belongs to the Special Issue Therapeutic Vaccines and Cancer Immunotherapy)
PDF [209 KB, uploaded 12 August 2018]


The field of genitourinary malignancies has been a showcase for therapeutic cancer vaccine success since the application of intravesicular Bacillus Calmette-Guerin (BCG) for bladder cancer in the 1970s and enjoyed a renaissance in 2010 with the US Food and Drug Administration (FDA) approval of sipuleucel-T for prostate cancer. Several vaccine strategies have emerged, such as autologous or allogeneic whole-tumor vaccines, DNA vaccines, use of viral vectors, and peptides as immunostimulatory adjuvants. Despite impressive early trials, vaccine monotherapy has achieved limited success in the clinical world; however, combinations of vaccine and immune checkpoint inhibition or vaccine and cytokine stimulation are expected to move the field forward. This article reviews pivotal trials of cancer vaccines in prostate, renal, and bladder cancer and ongoing trials combining vaccines with other immune therapy agents. View Full-Text
Keywords: prostate cancer; renal cell cancer; bladder cancer; cancer immunotherapy; therapeutic cancer vaccine; combination therapies prostate cancer; renal cell cancer; bladder cancer; cancer immunotherapy; therapeutic cancer vaccine; combination therapies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Dutcher, G.M.A.; Bilen, M.A. Therapeutic Vaccines for Genitourinary Malignancies. Vaccines 2018, 6, 55.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top